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Summary  
The clinical effectiveness of patient-controlled analgesia has been demonstrated in a 
variety of settings. However, patient-controlled analgesia is rarely utilised in the 
emergency department. The aim of this study was to compare the cost-effectiveness of 
patient-controlled analgesia vs. standard care in participants admitted to hospital from the 
emergency department with pain due to traumatic injury or non-traumatic abdominal pain. 
Pain scores were mea-sured hourly for 12 h using a visual analogue scale. Cost-
effectiveness was measured as the additional cost per hour in moderate to severe pain 
avoided by using patient-controlled analgesia rather than standard care (the incre-mental 
cost-effectiveness ratio). Sampling variation was estimated using bootstrap methods and 
the effects of parameter uncertainty explored in a sensitivity analysis. The cost per hour 
in moderate or severe pain averted was estimated as £24.77 (€29.05, US$30.80) 
(bootstrap estimated 95%CI £8.72 to £89.17) for participants suffering pain from 
traumatic injuries and £15.17 (€17.79, US$18.86) (bootstrap estimate 95%CI £9.03 to 
£46.00) for participants with non-traumatic abdominal pain. Overall costs were higher with 
patient-controlled analgesia than standard care in both groups: pain from traumatic 
injuries incurred an additional £18.58 (€21.79 US$23.10) (95%CI £15.81 to £21.35) per 
12 h; and non-traumatic abdominal pain an additional £20.18 (€23.67 US$25.09) (95%CI 
£19.45 to £20.84) per 12 h. 
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Patient-controlled analgesia (PCA) using intravenous (i.v.) opioids has been a standard of 
care for many patients following surgery for over 20 years [1, 2]. However, in some clinical 
settings such as the emergency department, PCA has not been routinely adopted into 
clinical practice. The few trials which have tested the use of PCA in this setting have 
shown that it is as effective as nurse-titrated analgesia. However, almost all the studies 
were limited to the initial 4 h of care [3, 4]. The clinical effectiveness of PCA in the 
emergency department has been confirmed, but in order for this analgesic modality to be 
widely adopted, evidence for cost-effectiveness is also required [3]. The cost-
effectiveness of PCA for postoperative pain relief was extensively investigated in the 
1990s and the drivers of the marginal costs were identified as the cost of equipment, 
analgesic drugs, and staff time. As the use of PCA has become routine practice in many 
circumstances, there have been fewer new studies, and none in the emergency 
department setting. [5] 
 
This paper describes the results of an economic evaluation that was part of the PAin 
SoluTions In the Emergency Setting (PASTIES) trial [6]. In summary, PASTIES comprised 
two parallel multicentre open label, randomised trials of PCA vs. standard care that were 
statistically powered separately, but run side-by-side using a shared protocol. Pain scores 
were recorded hourly for the first 12 h, and the total pain experienced was calculated as 
the area under the curve. 
 
The aim of this economic study was to evaluate the cost per hour required to avoid 





Full details of the protocol for the PASTIES trials have been published previously [6]. In 
brief, the patient populations were adult patients attending the emergency department with 
pain from either traumatic injuries or non-traumatic abdominal pain, who were admitted to 
an in-patient ward. Patients with chronic pain or a history of significant opioid use were not 
studied. Participants recorded a pain score at hourly intervals over 12 h following their 
recruitment to the study. Pain scores were recorded using a visual analogue scale in the 
form of a 100-mm line anchored with ‘no pain’ at one end and ‘worst pain possible’ at the 
other end. Pain scores were recorded as the distance in millimetres from the ‘no pain’ end 
of the scale. Moderate to severe pain was defined by a pain score ≥ 45 mm [7]. 
Participants also recorded periods of sleep retrospectively and, for the purposes of the 
main economic evaluation, these have been regarded as occasions when they were not in 
moderate to severe pain. 
 
The study samples for this economic evaluation were drawn from participants recruited 
to the PAS-TIES study (n = 196 with abdominal pain and n = 200 with pain related to 
traumatic injury). An opportunistic sample of 20 participants (10 in the PCA group and 10 
in the standard care group) was used for the observational time and motion study, equally 
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divided between those with pain due to trauma and abdominal pain. Participants were 
observed over the 12 h of the economic study and the time health-care staff engaged in 
pain management activities was recorded. The marginal costs of PCA in participants with 
traumatic injuries and those with non-traumatic abdominal pain were assessed separately. 
 
Patient-controlled analgesia equipment costs have been estimated based on the NHS 
purchase price of the Graseby 3300 PCA device (Smiths Medical Inter-national Ltd., 
Hythe, UK) assuming a 5-year useful life. For the main analysis, the per participant   
equipment cost has been estimated on the basis that the PCA equipment is not available 
for other use for 24 h, and includes the costs of drugs (morphine sulphate 1 mg.ml-1 
solution for injection), porterage, disposables, cleaning, servicing and maintenance costs. 
Pump maintenance costs during use have been treated as staff activity and valued as 
staff time. Estimates of the costs of staff time were derived from an observational study of 
the various activities entailed in pain management in the emergency department and 
ward. The timings for the various activities were similar to those reported in a large time 
and motion study, with the exception of the time taken to instruct participants in the use of 
the PCA equipment [8]. Due to the possibility that the observation conflated PASTIES 
study instructions with PCA use, a separate study of PCA instruction in routine care in the 
post-anaesthetic care unit was used to estimate timings for this aspect of staff time. 
Variation in the costs of the individual tasks reflects both variation in the time taken and 
range of professions and grades of staff who undertook them. The staff costs for 
categories of analgesic-related activities were estimated by sampling the distributions 
found in the observational study. Drug use for study participants was captured from their 
medical records and was costed as NHS prices from the British National Formulary [9]. 
Cost-effectiveness is reported as the additional cost per hour in moderate to severe pain 
avoided by using PCA rather than standard care, namely the incremental cost-
effectiveness ratio. Sampling variation was estimated using bootstrap methods and the 
effects of parameter uncertainty explored in sensitivity analysis. 
 
Results  
Costs were significantly greater in the PCA arm of both trials: traumatic pain additional 
cost £18.58 (95% CI £15.81 to £21.35) (€21.79 US$23.10); and non-traumatic abdominal 
pain additional cost £20.18 (95%CI £19.45 to £20.84) (€23.67 US$25.09). In the traumatic 
pain trial, PCA participants spent, on average, less time in moderate or severe pain 
(36.2% vs. 44.1%; mean difference (CI) 7.8 ( 1.0 to 16.5)%), but the difference was not 
statistically significant (p = 0.081) [10]. In the abdominal pain trial, PCA participants spent 
significantly less of the study period in moderate or severe pain (32.6% vs. 46.9%; mean 
difference (CI) 14.5 (5.6–23.5)%, p = 0.002) [11]. 
 
The mean (SD) costs of analgesic and anti-emetic drugs used in the traumatic pain 
trial were £8.44 (12.15) (€9.90 US$10.49) in the PCA group and £5.32 (6.79) (€6.24 
US$6.61) in the standard care group. For the abdominal pain trial, the mean (SD) drug 
costs were £7.79 (1.95) (€7.79 US$9.69) in the PCA group and £3.28 (2.24) (€3.85 
US$4.08) in the standard care group. 
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The results of the observational study are summarised in Table 1. This shows the 
timings for categories of analgesic-related staff activities together with the associated 
employment. Overall, the average staff costs (SD) in the traumatic pain trial were 
estimated as £8.42 (0.82) (€9.87 US$10.47) for the PCA group and £6.70 (0.99) (€7.86 
US$8.33) for the standard care group. 
 
 
Table 1 Time and staff costs for patient-controlled analgesia and standard care groups per 
participant during the 12-h study period. Values are mean (SD). 
 
PCA group Time; min Cost; £ 
    
Drug chart 2.5 (1.3) 0.8 (0.4) 
Set up 13.4 (4.2) 3.3 (1.2) 
PCA instruction 7.0 (4.3) 2.0 (1.1) 
Pain scoring 3.8 (1.3) 1.0 (0.3) 
Further analgesia 7.2 (12.7) 1.7 (3.2) 
PCA maintenance 3.0 (15.5) 0.8 (1.0) 
Nausea management 0.7 (3.3) 0.2 (0.6) 
Additional vital signs 
measurement 0.5 (1.2) 0.1 (0.3) 
Standard care group    
Drug chart 3.5 (1.6) 1.7 (1.1) 
Administration of 
analgesia 7.8 (9.6) 5.0 (5.2) 
Reassessment of pain 5.0 (2.6) 1.2 (0.6) 
Further analgesia 7.4 (2.0) 2.0 (1.5) 
i.v. line 1.3 (2.5) 0.3 (0.6) 
 
PCA, patient-controlled analgesia; i.v., intravenous. 
 
In the abdominal pain trial the estimates of the average staff costs (SD) were £8.30 (0.84) 
(€9.73 US $10.32) for PCA participants and £6.64 (1.10) (€7.79 US$8.26) for the standard 
care group. 
 
The annual costs of the PCA equipment were £1265 (€1484 US$1573) comprising 
depreciation, electrical testing, calibration and rebuild costs, allowing for 2 days down-time 
for servicing. The annual costs equate to £3.49 (€4.09 US$4.34) per day. The per-use 
costs, comprising drugs, disposables, porterage, cleaning and maintenance amounted to 
£11.02 (€12.92 US $13.70), making the total cost used in the primary analysis £14.51 
(€17.02 US$18.04). 
 
The results of the economic evaluation of the traumatic pain trial are summarised in 
Table 2. The cost per hour in moderate or severe pain averted (incremental cost 
effectiveness ratio) was estimated as £24.77 (€29.05, US$30.80) (bootstrap estimated 
95%CI £8.72 to £89.17). The results of the economic evaluation of the abdominal pain 
trial are summarised in Table 3. The incremental cost-effectiveness ratio for participants 
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with abdominal pain was estimated as £15.17 (€17.79, US$18.86) (bootstrap estimated 




Table 2 Economic evaluation of traumatic pain trial. Values are mean (SD). 
 
   Standard 
care group 
n = 101 
 
PCA group 
n = 99 
 
     
Staff costs; £ 7.63 (0.79) 6.68 (1.35) 
Drug costs; £ 8.44 (12.14) 5.32 (6.79) 
Patient-controlled 14.51 - 
analgesic device cost; 
£     
Total costs 
30.58 (12.14) 12.00 (7.10) 
Time in moderate 3.95 (3.64) 4.70 (3.58) 
or severe pain; h     
 






Table 3 Economic evaluation of abdominal pain trial. Values are mean (SD). 
 
    Standard 
  PCA group care group 
  n = 99 n = 101 
     
Staff costs; £ 7.64 (0.97) 6.48 (1.34) 





 device cost; £    
Total costs 
29.9
4 (2.19) 9.76 (2.47) 
Time in moderate or 3.95 (4.13) 5.28 (3.70) 
 severe pain; h    
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The sampling variation associated with the estimate of the incremental cost 
effectiveness ratio in the traumatic pain trial is illustrated in Fig. 1, which shows the 
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Figure 1 Sampling variation for traumatic pain trial: incremental cost-effectiveness ratio estimates from 1000 boot-
strap samples shown on the cost-effectiveness plane. 
 
 
The variation in the estimated marginal costs is relatively small, ranging from £14.11 to 
£21.87 (€16.55 to €25.65 US$17.54 to US$27.19), while the estimates for additional 
hours in moderate or severe pain range from 1.07 h to 2.33 h for standard care groups. 
The cost-effectiveness accept-ability curve illustrates effects of the sampling uncertainty 
in terms of how likely it is that the use of PCA will prove effective given a specified 
willingness to pay to avert an hour in moderate to severe pain. For example, if a decision 
taker were willing to pay £40 (€47 US $50) to avert an hour in moderate to severe pain, 
the probability of achieving that hour for that cost would be 0.829 (Fig. 2). For abdominal 
pain, the estimates of the marginal costs of PCA lie between £18.86 and £21.47 (€22.12 
to €25.18 US$23.45 to US$26.70), and estimates for hours in pain between 0.68 
additional hours in pain to 3.39 fewer hours in pain (Fig. 3). At a willingness to pay cost of 
£40 (€47 US$50) the probability of realising the aim of averting an hour in moderate to 
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Figure 3 Sampling variation for abdominal pain trial: incremental cost-effectiveness ratio 
estimates from 1000 boot strap samples shown on the cost-effectiveness plane  
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Figure 4 Cost-effectiveness acceptability curve, abdominal pain trial. 
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There was considerable variation in the numbers of hourly pain observations for 
participants in the two trials, for the most part because of the different amounts of time 
participants spent asleep. The primary economic analysis did not take account of 
differences in the ‘time at risk’ on the grounds that the currency for the evaluation was 
hours in pain. However, although differences in the average numbers of observations 
between PCA and standard care groups were relatively small, it is possible that they may 
affect the estimate of marginal differences in hours in pain and hence the estimate of the 
incremental cost effectiveness ratio. To gauge the extent of any such effect, for each 
individual the proportion of waking hours in pain was multiplied by the mean number of 
hours observed in the trial. For the traumatic pain trial the mean hours observed was 
8.31, so for this analysis the proportion of each individual’s waking hours in pain were 
multiplied by 8.31 to give a ‘standardised’ measure of hours in pain. On this basis, the 
additional cost per hour in pain averted was £31.50 (€36.94 US $39.17) (bootstrap 
estimate 95%CI £14.29 to £88.71). This estimate is higher than that from the main    
analysis, reflecting a reduced estimate of marginal effective-ness of PCA. For the 
abdominal pain trial the average hours observed was 9.10. On this basis, the estimate of 
the additional cost per hour in pain averted was £15.06 (€17.66 US$18.73) (bootstrap 
estimate 95%CI £11.04 to £36.22), similar to the estimate in the main analysis. 
The estimated costs of the PCA equipment represent a substantial proportion of the 
additional costs associated with PCA, and more than half of the marginal costs in the 
abdominal pain trial. The cost assumptions used in the main analysis are that the 
equipment is purchased, with servicing and maintenance provided in-house. It has not 
been possible to find a cheaper leasing contract but comparisons are complicated 
because leading suppliers offer leasing arrangements supported by a wide range of 
accessories, training and maintenance service agreements. If equipment costs were to 
be completely excluded from the analysis (Scalley et al., for example, regarded them as 
sunk costs [12]), it would reduce the marginal cost by £3.49 (€4.09 US$4.34) and the 
incremental cost effectiveness ratio by £4.65 (€5.45 US$5.78) for the traumatic pain trial, 
and £2.62 (€3.07 US$3.26) for the abdominal pain trial. The costs of staff time were 
based on the times per patient measured in the observational study. Both PCA and 
standard care pain relief have best practice schedules of observations and pain 
assessment, which were not always followed during the observational study. With the 
activity costs from the observational study it is possible to estimate the staff costs as they 
would be if the protocols were strictly observed. This results in an increase in the 
estimate of staff costs in both trials for both treatment groups. In the traumatic pain trial 
average staff costs would increase by £1.54 (€1.81 US$1.91) in the PCA group and 
£4.43 (€5.20 US$5.51) in the standard care group, resulting in an estimate of the 
incremental cost-effectiveness ratio of £22.91 (€26.87 US$28.49) (bootstrap 95%CI 
£7.54 to £87.97). In the abdominal pain group staff costs would increase by £3.48 (€4.08 
US$4.33) in the PCA group and £1.83 (€2.15 US$2.28) in the standard care group, with 
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an estimated incremental cost effectiveness ratio of £15.89 (€18.63 US$19.76) (boot-
strap 95%CI £8.71 to £51.23). 
 
Discussion  
Patient-controlled analgesia has been shown to be safe and effective in a variety of 
settings including postoperative pain management, burns and painful medical conditions 
[5, 13, 14]. Patient satisfaction with analgesia is correlated with involvement in pain 
manage-ment, no requirement for further analgesia, and the amount of pain relief received 
[15]. As PCA provides these conditions, it is usually popular with patients. Analgesia for 
patients managed in the emergency department is usually provided by nurse-delivered 
intermittent boluses of i.v. morphine. This practice is safe and effective in the short term, 
but places significant demands on nursing time, particularly when repeated doses are 
needed [16]. Despite this well-established approach, pain is often not treated effectively in 
the emergency department setting [17]. 
 
In common with previous economic evaluations of PCA technology in other settings, 
this evaluation found that the use of PCA for patients presenting to emergency 
departments with traumatic or abdominal pain reduced the amount of time they 
experienced moderate or severe pain, at an additional cost. 
 
Health economic studies of acute pain are uncommon. Recently, however, a study of 
the impact of acute postoperative pain has revealed significant reductions in health-
related quality of life using tools such as the EQ5D [18]. In this study, the cost-
effectiveness of PCA was reported as the additional cost per hour in moderate to severe 
pain averted rather than in terms of quality-adjusted life years (QALY). In part, this reflects 
the aims and design of the two PASTIES clinical trials. Both trials included patients with a 
wide range of conditions with different associated patterns in quality of life and costs over 
time. The assessment of these diverse patterns was beyond the scope of the PASTIES 
trial, which focussed on the alleviation of pain during the relatively brief 12-h period 
following recruitment. More speculatively, it is not clear that acute pain in an emergency 
department setting would meet the QALY assumption of constant proportional trade-off; it 
seems likely that the inutility of an episode of acute pain is not constant with respect to its 
duration. 
The comparatively short intervention period for the PASTIES study meant that the cost 
and benefits of PCA use, relative to standard care, were not assessed beyond the first   
12 h. Longer term effects and costs of PCA use can be expected to be condition-specific 
and beyond the scope of this study. Chronic pain is common, affecting 20% of the general 
population in Europe and 18% of postoperative patients [19, 20]. The costs of chronic pain 
to the health service is significant; for example, 20% of the total health expenditure in the 
UK is used to treat chronic back pain [21]. It is known that acute pain correlates strongly 
with chronic pain at 6 months, and it is possible that PCA use may be associated with a 
reduction in chronic pain [22]. However, in emergency departments, decisions about pain 
relief are, as a rule, clinically exigent and can be reliably informed by immediate marginal 
costs and effectiveness of the alternative approaches. 
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Although this study demonstrated an increased drug cost for PCA, previous findings 
are equivocal. In comparison with conventional pain management, some studies have 
reported higher drug costs associated with PCA use [12, 23, 24] while others found that 
drug costs were lower [25–27]. Findings related to staff costs are more consistent, with 
PCA use being associated with lower costs [25, 28, 29]. Differences in the detailed 
findings possibly come about because individual studies have looked at the cost-
effectiveness of postoperative PCA use following a range of procedures, in a variety of 
different healthcare systems and using an assortment of approaches to costing. Once 
PCA equipment costs are taken into account, however, almost all of the studies agree that 
PCA provides more effective pain relief at higher cost. 
 
There are potential weaknesses of this study, two of which, the management of time 
asleep and the cost of PCA devices, are discussed above. Additionally, bias may have 
been introduced in the sampling process for the observational study, as patient selection 
was opportunistic, rather than randomised. Pain score data were drawn from participants 
at all sites enrolled in the PASTIES multicentre trial, whereas the observational study was 
based at the primary site only. Although the PCA devices were leased by some centres 
and pur-chased by others, there were very similar clinical protocols for PCA use, and it is 
unlikely that this will impact on clinical effectiveness. It would, therefore, seem reasonable 
to include all sites when calculating the incremental cost-effectiveness ratio. 
 
This study presents the first evaluation of the incremental cost-effectiveness of the use 
of PCA in the emergency setting, following patients onto a hospital ward after admission 
from emergency department. The evaluation of the additional costs and pain relief     
associated with PCA in this setting provides useful additional information for clinical and 
service decision-makers regarding the incorporation of PCA in the management of 
patients presenting to an emergency department in pain. 
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